

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7170478

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TOWA PHARMACEUTICAL EUROPE S.L. UNIPERSONAL	02/08/2022
RECEIVING PARTY DATA	
Name:	BRECKENRIDGE PHARMACEUTICAL, INC.
Street Address:	15 MASSIRIO DRIVE
Internal Address:	SUITE 201
City:	BERLIN
State/Country:	CONNECTICUT
Postal Code:	06037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	11013729
CORRESPONDENCE DATA	
Fax Number:	(612)332-9081
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	16123325300
Email:	lkenney@merchantgould.com
Correspondent Name:	MERCHANT & GOULD
Address Line 1:	P.O. BOX 2903
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	70204.0018USC1
NAME OF SUBMITTER:	MELISSA M. HAYWORTH
SIGNATURE:	/Melissa M. Hayworth/
DATE SIGNED:	02/10/2022
Total Attachments: 2	
source=0018USC1_Assignment-Towa-Breckenridge#page1.tif	
source=0018USC1_Assignment-Towa-Breckenridge#page2.tif	

**ASSIGNMENT – TRANSFER OF OWNERSHIP
FOR THE UNITED STATES**

Towa Pharmaceutical Europe S.L. Unipersonal, a Spanish Corporation (hereinafter "Assignor"), having its registered office located at Poligon Industrial de Martorelles, Carrer de Sant Marti, 75-97, 08107 Martorelles (Barcelona), Spain, is the owner/applicant of record of the following:

U.S. Application No. 14/379,613, filed August 19, 2014, entitled "Oral
Pharmaceutical Compositions of Dabigatran Etexilate," now
United States Patent No. 11,013,729 issued 25 May 2021; and

U.S. Application No. 17/241,793, filed April 27, 2021, entitled "Oral
Pharmaceutical Compositions of Dabigatran Etexilate"

by virtue of assignment documents recorded in the U.S. Patent and Trademark Office.

Whereas, Breckenridge Pharmaceutical, Inc., a Florida corporation with a principal place of business at 15 Massirio Drive, Suite 201, Berlin, CT 06037 (hereinafter "Assignee"), has acquired the rights for the United States to the above inventions, improvements, applications, and any U.S. Patents obtained therefrom. The effective date of this transfer being 7 December 2021.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, Assignor did hereby transfer and assign to Assignee, the entire United States rights, title and interest in and to all inventions and improvements disclosed in the aforesaid applications for the United States, including all U.S. patent applications based upon said applications, all divisions, continuations, or renewals thereof, all U.S. Letters Patents which may be granted therefrom, and all reissues or extensions of such patents.


I do hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all United States Letters Patent for the aforesaid inventions and improvements to the Assignee as the assignee of the entire right, title and interest in and to the same, for the use of the Assignee, its successors and assigns.

Assignor has caused this Assignment to be duly executed by its authorized representative on the date set forth below. Assignee acknowledges receipt of this Assignment as executed by its authorized representative on the date set forth below.

ASSIGNMENT – TRANSFER OF OWNERSHIP

Dated: February 8th, 2022

TOWA PHARMACEUTICAL EUROPE S.L. UNIPERSONAL

By: 

Typed Name: David Peix Gallofré


Title: Joint and Several Administrator

TOWA PHARMACEUTICAL EUROPE S.L. UNIPERSONAL

Acknowledged by:

Dated: Feb 9th, 2022

BRECKENRIDGE PHARMACEUTICAL, INC.

By: 

Typed Name: Brian Guy

Title: President and Chief Commercial Officer

BRECKENRIDGE PHARMACEUTICAL, INC.